XT
TCRX icon

XTX Topco’s TScan Therapeutics TCRX Stock Holding History

XTX Topco’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146K Buy
149,467
+88,747
+146% +$94.6K ﹤0.01% 3394
2026
Q1 		$61.3K Sell
60,720
-158,281
-72% -$169K ﹤0.01% 3259
2025
Q4 		$219K Buy
219,001
+201,375
+1,142% +$291K 0.01% 2329
2025
Q3 		$32.1K Buy
+17,626
New +$31.2K ﹤0.01% 2250
2024
Q4 		– Sell
-22,438
Closed -$112K – 2919
2024
Q3 		$112K Buy
+22,438
New +$135K 0.01% 1590

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $812M AUM 2.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

XTX Topco's TCRX Position: Q2 2026 in Review

XTX Topco increased its TScan Therapeutics (TCRX) stake by 146% in Q2 2026, buying an estimated $94.6K and bringing the position to 149,467 shares worth $146K. The position accounts for ﹤0.01% of the portfolio, ranked #3394.

XTX Topco first reported a position in TCRX in Q3 2024 and has held it in 5 quarters since. The position peaked at $219K in Q4 2025. 60 funds tracked by Wall St. Rank hold TCRX as of Q2 2026.

  • XTX Topco held 149,467 shares of TScan Therapeutics worth $146K as of Q2 2026.
  • XTX Topco bought 88,747 TScan Therapeutics shares in Q2 2026, an estimated $94.6K.
  • TScan Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3394 holding.
  • XTX Topco first reported a position in TScan Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • XTX Topco's TScan Therapeutics position peaked at $219K in Q4 2025.
  • 60 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.